The monoclonal IgG1 antibody BIIB076 (Czerkovicz et al., 2018) is classified as a pan-tau antibody and is reported to target monomeric and fibrillary forms of tau pathology, without regard to whether they are specific for AD. The gene discussed is MAPT; the disease is Alzheimer disease.